Publications by authors named "Lanqi Ren"

Claim this Profile
R
Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study.
Yidong Zhou, Fei Tong, Bowen Jin, Junjie Pan, Ning Ren, Lanqi Ren

J Gynecol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferroptosis: a new promising target for hepatocellular carcinoma therapy.
Qiaoping Xu, Lanqi Ren, Ning Ren, Yibei Yang, Junjie Pan

Mol Cell Biochem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functions and mechanisms of RNA mA regulators in breast cancer (Review).
Yibei Yang, Feng Gao, Lanqi Ren, Ning Ren, Junjie Pan

Int J Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of N‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).
Junjie Pan, Fei Tong, Ning Ren, Lanqi Ren, Yibei Yang

Oncol Rep· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
Junjie Pan, Ning Ren, Lanqi Ren, YiBei Yang, Qiaoping Xu

Sci Rep· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA m6A methylation regulators in liver cancer.
Qiaoping Xu, Ning Ren, Lanqi Ren, Yibei Yang, Junjie Pan

Cancer Cell Int· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer.
Lanqi Ren, Ning Ren, Yu Zheng, Yibei Yang, Qiaoping Xu

Front Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis